I'm LongbridgeAI, I can summarize articles.Gyre Therapeutics released an updated corporate presentation detailing pipeline progress, China strategy, and regulatory milestones. Key highlights include positive Phase 3 topline results for F351 in CHB-associated liver fibrosis and NMPA acceptance of its NDA by May 2026. The company emphasizes leveraging China operations to enhance R&D efficiency and reduce costs. Clinical updates show CG001419 advancing into Phase 1b expansion with no dose-limiting toxicities, while CG009301 is undergoing dose escalation.
Gyre made available an updated corporate presentation highlighting pipeline progress, China-enabled R&D efficiency and regulatory milestones including an NMPA acceptance for F351.
Key Highlights:
- Updated corporate presentation posted on Gyre’s website (furnished as Exhibit 99.1) under Regulation FD disclosure.
- F351 (hydronidone) reported positive Phase 3 topline results for CHB-associated liver fibrosis and NDA accepted by NMPA in May 2026.
- Gyre emphasizes China operations to accelerate discovery, validation and development and to reduce costs across R&D, manufacturing and commercialization.
- Pipeline spans discovery to marketed products: ETUARY™ marketed, multiple degraders/DACs and candidates (CG923308, CG620953, CG001419, CG009301) in development.
- Clinical updates: CG001419 progressed into Phase 1b expansion with no DLTs observed in first 22 patients; CG009301 dose escalation underway with no DLTs in first eight patients.
Original SEC Filing: GYRE THERAPEUTICS, INC. [ GYRE ] - 8-K - Jun. 02, 2026